MBX Biosciences, Inc.(MBX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash posit ...